Showing 6581-6590 of 9134 results for "".
- Verrica Pharmaceuticals: Positive Data for VP-102 for Molluscum Contagiosum, Wartshttps://practicaldermatology.com/news/verrica-pharmaceuticals-positive-data-for-vp-102-for-molluscum-contagiosum-warts/2460187/Positive data for VP-102 (cantharidin 0.7% Topical Solution) from Verrica Pharmaceuticals, Inc. are being presented in poster form at the Annual Fall Clinical Dermatology Conference in Las Vegas. Company’s lead product candidate is being developed for the treatment of molluscum c
- UCB’s Bimekizumab Performs Well in Phase 3 Psoriasis Studyhttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-phase-3-psoriasis-study/2460186/UCB’s bimekizumab, an IL-17A and IL-17F inhibitor, bested placebo and Stelara (ustekinumab) when it came to clearing the skin of patients with moderate-to-severe chronic plaque psoriasis and improving their symptoms, the company reports. BE VIVID is the first of three Phase 3
- Psoriasis Linked to Developing and Dying from Cancerhttps://practicaldermatology.com/news/psoriasis-linked-to-developing-and-dying-from-cancer/2460185/Psoriasis may increase the risk for certain cancers, according to a review of 58 studies published in JAMA Dermatology. Moreover, the risk of dying from certain site-specific cancers was elevated in those with severe psoriasis. Specifically, severe psoriasi
- Botox Hits the Big 3-0https://practicaldermatology.com/news/botox-hits-the-big-3-0/2460184/Botox is turning 30, and Allergan fêted its shining star, Botox Cosmetic, in style at a New York City bash. The event included the debut of Botox Cosmetic’s new packaging and a panel discussion featuring New York City dermatologists Macrene Alexiades-Armenakas, MD, PhD
- Obagi Program at ASDS to Focus on Inclusionhttps://practicaldermatology.com/news/obagi-program-at-asds-to-focus-on-inclusion/2460183/Obagi and actor, producer and activist, Priyanka Chopra Jonas, will lead a panel of top dermatologists in a discussion about the importance of diversity and inclusion in medical aesthetics during the annual meeting of the American Society for Dermatologic Surgery (ASDS) in Chicago next week. 
- Altreno: Exclusive Size Available for Dermatologist Dispensinghttps://practicaldermatology.com/news/altreno-exclusive-size-available-for-dermatologist-dispensing/2460182/Altreno (tretinoin) Lotion, 0.05%, is now available exclusively for physician dispensing in a 20-gram size. Launched last year, Altreno Lotion from Ortho Dermatologics is the first and only tretinoin available in a lotion for the treatment of acne that has been shown to be effectiv
- Expert Second Opinion Improves Reliability of Melanoma Diagnoseshttps://practicaldermatology.com/news/expert-second-opinion-improves-reliability-of-melanoma-diagnoses/2460179/Obtaining a second opinion from pathologists who are board certified or have fellowship training in dermatopathology may improve the accuracy and reliability of diagnosing melanoma, according to a new study in JAMA Network Open. To evaluate the impact of obtaining second o
- Pediatric AD Takes Its Toll on Caregiver Emotional Wellbeinghttps://practicaldermatology.com/news/ad-takes-its-toll-on-caregiver-emotional-wellbeing/2460173/Family members and caregivers of children with atopic dermatitis (AD) may be at increased risk for anxiety and depression, according to new research presented at the 28th European Dermato-Venereology Society Congress in Madrid. Researchers from the PHIUniversity Clinic of Dermatol
- Positive Phase 2 Results Seen With Galderma’s Proprietary Liquid Toxin for Frown Lineshttps://practicaldermatology.com/news/positive-phase-2-results-seen-with-galdermas-proprietary-liquid-toxin-for-frown-lines-2/2460170/Galderma’s novel liquid abotulinum toxin, QM1114, is safe and effective for the treatment of glabellar lines, according to Phase 2 study results. Pivotal Phase 3 trials for Galderma's liquid formulation of botulinum toxin type A for the treatment of glabellar lines are expecte
- It's Grant Time: La Fondation La Roche-Posay Calls for Scientific Abstractshttps://practicaldermatology.com/news/its-grant-time-la-fondation-la-roche-posay-calls-for-scientific-abstracts/2460169/Calling all residents, fellows, and practitioners within their first five years of practice: La Fondation La Roche-Posay (North American) is now accepting submissions for their 2020 grants program. Three grants for $10,000, $5,000 & $5,000 will be awarded for innovative program